Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | ACACA | Q13085 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25439886 | 0.98 | ALOX5 (0.45) | ALOX5PTGS1NPY5RSMN1; SMN2ACACB | |
| SCHEMBL20564588 | 0.90 | ALOX5 (0.41) | ALOX5PTGS1NPY5RSMN1; SMN2ACACB | |
| SCHEMBL25440144 | 0.89 | TSHR (0.44) | ALOX5SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL26324957 | 0.86 | PTGS1 (0.41) | ALOX5PTGS1NPY5RSMN1; SMN2ACACB | |
| SCHEMBL25439798 | 0.85 | TRPM8 (0.40) | ALOX5SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL25439854 | 0.85 | PDCD1 (0.53) | SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL26324995 | 0.84 | PTGS1 (0.42) | ALOX5PTGS1NPY5RSMN1; SMN2ACACB | |
| SCHEMBL25440154 | 0.83 | PDCD1 (0.54) | SMN1; SMN2 | |
| SCHEMBL25440240 | 0.81 | KMT2A (0.40) | SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL26327814 | 0.80 | LTA4H (0.44) | NPY5RSMN1; SMN2MAPK1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767291-B2 | Preparation of secondary amines with electrophilic N-linchpin reagents | WILLIAM MARSH RICE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767291-B2 | Preparation of secondary amines with electrophilic N-linchpin reagents | PNMT, NCL, NPM1 | ALOX5 2561/4885PTGS1 4470/4885NPY5R 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.